Belite Bio Adr Stock Today
| BLTE Stock | USD 68.38 0.57 0.84% |
PerformanceInsignificant
| Odds Of DistressBelow Average
|
Belite Bio is trading at 68.38 as of the 19th of March 2025, a 0.84% increase since the beginning of the trading day. The stock's lowest day price was 67.4. Belite Bio has about a 26 % chance of experiencing some form of financial distress in the next two years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of April 2022 | Category Healthcare | Classification Health Care |
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd. The company has 31.84 M outstanding shares of which 69.35 K shares are currently shorted by private and institutional investors with about 2.47 trading days to cover. More on Belite Bio ADR
Moving against Belite Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Belite Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsBelite Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Belite Bio's financial leverage. It provides some insight into what part of Belite Bio's total assets is financed by creditors.
| |||||
Belite Bio ADR (BLTE) is traded on NASDAQ Exchange in USA. It is located in 12750 High Bluff Drive, San Diego, CA, United States, 92130 and employs 20 people. Belite Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.18 B. Belite Bio ADR conducts business under Biotechnology sector and is part of Health Care industry. The entity has 31.84 M outstanding shares of which 69.35 K shares are currently shorted by private and institutional investors with about 2.47 trading days to cover.
Belite Bio ADR currently holds about 48.7 M in cash with (29.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.96.
Check Belite Bio Probability Of Bankruptcy
Ownership AllocationBelite Bio holds a total of 31.84 Million outstanding shares. Belite Bio ADR retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Belite Ownership Details
Belite Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bnp Paribas Arbitrage, Sa | 2024-12-31 | 2.5 K | |
| Rhumbline Advisers | 2024-12-31 | 1.4 K | |
| Gamma Investing Llc | 2024-12-31 | 1.3 K | |
| Virtus Etf Advisers Llc | 2024-12-31 | 1.1 K | |
| Advisors Preferred, Llc | 2024-12-31 | 798 | |
| Mirae Asset Global Investments (korea) Co Ltd | 2024-12-31 | 357 | |
| Sbi Securities Co Ltd | 2024-12-31 | 14.0 | |
| Quantbot Technologies Llc | 2024-12-31 | 11.0 | |
| Advisor Group Holdings, Inc. | 2024-12-31 | 7.0 | |
| Armistice Capital, Llc | 2024-12-31 | 167.9 K | |
| State Street Corp | 2024-12-31 | 20 K |
Belite Bio Historical Income Statement
Belite Stock Against Markets
Belite Bio Corporate Management
| ChingChen MSc | VP Operations | Profile | |
| YuHsin MBA | Chairman CEO | Profile | |
| CFA FRM | CFO Director | Profile | |
| MA MD | Chief Board | Profile | |
| Nathan Mata | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Belite Bio ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Belite Bio. If investors know Belite will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Belite Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Belite Bio ADR is measured differently than its book value, which is the value of Belite that is recorded on the company's balance sheet. Investors also form their own opinion of Belite Bio's value that differs from its market value or its book value, called intrinsic value, which is Belite Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Belite Bio's market value can be influenced by many factors that don't directly affect Belite Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Belite Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Belite Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Belite Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.